Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua
Tigermed roars in its Hong Kong stock trading debut, as Asia’s largest health care IPO of 2020 draws traders to its clinical trials
- Clinical trial and research firm’s secondary listing was the biggest in Asia this year
- Will use funds to expand overseas
Follow your favourite topic and get notified
Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua
